Contents

Introduction ix

Minghan Wang

Contributors xi

Part One The Physiology of Metabolic Tissues Under Normal and Disease States

1. Gut as an Endocrine Organ: the Role of Nutrient Sensing in Energy Metabolism 3

Minghan Wang

2. Central Glucose Sensing and Control of Food Intake and Energy Homeostasis 29

Lourdes Mounien and Bernard Thorens

3. Abnormalities in Insulin Secretion in Type 2 Diabetes Mellitus 53

Taly Meas and Pierre-Jean Guillausseau

4. Adipokine Production by Adipose Tissue: A Novel Target for Treating Metabolic Syndrome and its Sequelae 73

Vanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, and Peter Zahradka

5. Hepatic Metabolic Dysfunctions in Type 2 Diabetes: Insulin Resistance and Impaired Glucose Production and Lipid Synthesis 133

Ruojing Yang
# Contents

6. Energy Metabolism in Skeletal Muscle and its Link to Insulin Resistance  
*Minghan Wang*  

Part Two Metabolic Diseases and Current Therapies

7. Mechanisms and Complications of Metabolic Syndrome  
*Minghan Wang*  

8. Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL  
*Margrit Schwarz and Jae B. Kim*  

9. Mechanism of Action of Niacin: Implications for Atherosclerosis and Drug Discovery  
*Devan Marar, Shobha H. Ganji, Vaijinath S. Kamanna, and Moti L. Kashyap*  

10. Current Antidiabetic Therapies and Mechanisms  
*Minghan Wang*  

Part Three Drug Targets for Antidiabetic Therapies

11. GLP-1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies  
*Remy Burcelin, Cendrine Cabou, Christophe Magnan, and Pierre Gourdy*  

12. Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes  
*C.H.S. McIntosh, S.-J. Kim, R.A. Pederson, U. Heiser, and H.-U. Demuth*  

13. Sodium Glucose Cotransporter 2 Inhibitors  
*Margaret Ryan and Serge A. Jabbour*  

14. Fibroblast Growth Factor 21 as a Novel Metabolic Regulator  
*Radmila Micanovic, James D. Dunbar, and Alexei Kharitonenk*  

15. Sirtuins as Potential Drug Targets for Metabolic Diseases  
*Qiang Tong*
## Contents

16. 11β-Hydroxysteroid Dehydrogenase Type 1 as a Therapeutic Target for Type 2 Diabetes  423  
*Clarence Hale and David J. St. Jean, Jr.*

17. Monoclonal Antibodies for the Treatment of Type 2 Diabetes: A Case Study with Glucagon Receptor Blockade  459  
*Hai Yan, Wei Gu, and Murielle Veniant-Ellison*

### Part Four Lessons Learned and Future Outlook

18. Drug Development for Metabolic Diseases: Past, Present and Future  471  
*Minghan Wang*

Index  489